OncoMatch/Clinical Trials/NCT07018050
Phase II Study of QLS32015 Combination Therapy in the Treatment of Multiple Myeloma
Is NCT07018050 recruiting? Yes, currently enrolling (Jun 2026). This Phase 2 trial studies multiple treatments for relapsed or refractory multiple myeloma.
Treatment: QLS32015 · Pomalidomide · Dexamethasone · QL2109 or Daratumumab · Bortezomib · Lenalidomide — The purpose of the study is to compare the efficacy of QLS32105 (SC) in combination with Pomalidomide, and QLS32105 (SC) in combination with QL2109 or Daratumumab, and QLS32105 (SC) in combination with QL2109 or Daratumumab and Pomalidomide, and QLS32105(SC) in combination with Bortezomib and Lenalidomide.
Check if I qualifyExtracted eligibility criteria
Treatments studied
Immunotherapy
Targeted therapy
Endocrine / hormonal
Other
Cancer type
Multiple Myeloma
Prior therapy
Must have received: anti-multiple myeloma therapy
Relapsed, progressed, or intolerant to ≥1 prior line of anti-multiple myeloma therapy
Cannot have received: GPRC5D-targeted therapy
Previous treatment with GPRC5D-targeted therapy
Cannot have received: genetically modified adoptive cell therapy (chimeric antigen receptor T-cell (CAR-T), natural killer (NK) cell therapy)
Genetically modified adoptive cell therapy (e.g., chimeric antigen receptor T-cell [CAR-T], natural killer [NK] cell therapy) within 3 months
Cannot have received: targeted therapy
Targeted therapy, investigational drugs, or invasive investigational medical devices within 21 days or 5 half-lives (whichever is longer)
Cannot have received: monoclonal antibody
Monoclonal antibodies or bispecific antibody therapy for multiple myeloma within 21 days or 5 half-lives (whichever is longer)
Cannot have received: cytotoxic chemotherapy
Cytotoxic therapy within 21 days
Cannot have received: proteasome inhibitor
Proteasome inhibitor therapy within 14 days
Cannot have received: immunomodulatory drug
Immunomodulatory drug therapy within 7 days
Structured fields extracted by AI. May contain errors — verify against the official protocol.
Frequently asked questions
Is NCT07018050 currently recruiting?
Yes, this trial is currently recruiting patients.
Are there prior therapy exclusions?
Yes. Prior GPRC5D-targeted therapy, genetically modified adoptive cell therapy, targeted therapy disqualifies patients from enrollment.
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualifyRelated pages